Leptin is a 16-kDa protein recently identified as the obese gene product involved in body weight regulation. Administration of recombinant leptin to ob/ob mice, which have a genetic defect in leptin production, reduces food intake and increases energy expenditure. Leptin is synthesized by fat cells, and in normal humans, plasma concentrations are proportional to adiposity. The physiological actions and the degradation pathways of leptin in humans are unknown. We investigated renal elimination of leptin by comparing plasma leptin concentrations in end-stage renal disease (ESRD) patients with normal controls. Our hypothesis was that if renal filtration is a significant route of elimination, the hormone would accumulate in ESRD patients. Mean plasma levels in 141 ESRD patients (26.8 Ϯ 5.7 and 38.3 Ϯ 5.6 g/L for males and females, respectively) were significantly higher (P Ͻ 0.001) than mean values obtained in normal controls (11.9 Ϯ 3.1 and 21.2 Ϯ 3.0 g/L for males and females, respectively). Leptin concentrations in ESRD patients correlated directly with body mass index (BMI; r ϭ 0.77 for men and 0.78 for women). The rate of increase in leptin concentrations with BMI was significantly greater in ESRD patients (5.5 and 6.6 g/L/U BMI for men and women, respectively) than in normal controls (1.4 and 2.6 g/L/U for men and women, respectively). Pre-and postdialysis leptin levels in hemodialysis patients were similar. Western blot of plasma from ESRD patients with high leptin levels showed bands corresponding to the intact protein (16 kDa) with no lesser or greater molecular mass species observed. Leptin concentrations in patients with ESRD did not correlate with measures of residual renal function (serum creatinine, ␤ 2 -microglobulin, PTH, or GH levels). Similarly, we found no correlation between leptin levels and the number of years patients had been on dialysis or with recent weight changes. We conclude that intact leptin is increased in ESRD patients, but does not appear to cause decreased weight. As leptin levels did not correlate with residual renal function, increased production may account for the high levels observed. (J Clin Endocrinol Metab 82: 847-850, 1997) L EPTIN, THE 16-kDa protein produced by the obese gene, is expressed and secreted by adipocytes and is known to regulate body weight and adipose tissue mass through a feedback mechanism (1-3). Administration of recombinant leptin to ob/ob mice, which have a genetic defect in leptin production, reduces food intake and increases energy expenditure (4 -6). Very little is known about the physiological actions of leptin in humans. Single genes may play a major role in obesity within certain families, but obesity in humans is believed to be a complex polygenic disorder. Several studies have shown a direct correlation between body fat mass and plasma leptin concentration in humans (7-10).
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Although degradation pathways of leptin have not been carefully investigated, several lines of indirect evidence suggest that renal clearance is the major route for leptin metabolism. First, the molecular weight and the calculated plasma half-life for leptin (9) are similar to those of other peptide hormones that are degraded by the proximal renal tubule (11) (12) (13) . Second, a recent study of the leptin receptor tissue distribution showed that the highest levels of expression of the receptor are seen in lung and kidney (14) .
The purpose of the present study was to investigate the importance of renal function in leptin clearance from plasma by 1) comparing plasma leptin concentrations in patients with end-stage renal disease (ESRD) with normal volunteers, 2) evaluating the relationship between plasma leptin concentrations and parameters of renal function, and 3) evaluating the relationship between plasma leptin concentrations and other peptide hormones that are affected by ESRD. We hypothesized that impaired leptin clearance by the kidney leads to an increase in the plasma leptin concentration. Therefore, patients with ESRD should have elevated plasma leptin concentrations, and this elevation should correlate with the severity of renal impairment. Aliquots taken from pre-and postdialysis plasma samples of ESRD patients were stored at Ϫ20 C and later used for leptin and other hormone measurements. All specimens were collected during routine dialysis hours (0700 -1600 h), and the subjects received their regular diet and medications. Residual renal function was determined in 24 patients by calculating creatinine clearance on a timed interdialytic urine collection. Adequacy of dialysis was assessed by determining the urea reduction ratio using a single pool method that accounted for the effects of ultrafiltration (15) .
Subjects and Methods Subjects

Leptin measurements
Plasma leptin concentrations were measured with a commercial RIA (Linco Research, St. Louis, MO) that has been previously evaluated (10) . The assay used purified recombinant human leptin as calibrators and a polyclonal antibody made to recombinant human leptin in rabbits. The assay limits of detection and linearity were 0.5 and 100 ng/mL, respectively (10). Leptin concentrations higher than 100 ng/mL were repeated on dilutions. The day to day precision of the assay, expressed as coefficients of variation, ranged from 3.6 -6.2% (10) . Plasma leptin levels were also measured by Western blot (10), omitting the immunoprecipitation step. The equivalent of 1.7 L plasma was diluted to 50 L in 30 g/L SDS, 50 g/L glycerol, and 62 mmol/L Tris-HCl (pH 6.7). Proteins were separated in 17% polyacrylamide gels and transferred to nitrocellulose. Leptin was stained with antibody made to recombinant human leptin (Linco Research) and peroxidase-conjugated second antibody (Sigma Chemical Co., St. Louis, MO). Chemiluminescence (ECL, Amersham, Little Chalfont, UK) was employed to visualize leptin for the generation of autoradiograms, which were quantitated with a IS-1000 imaging system (Alpha Innotech, San Leandro, CA). Results are reported as micrograms per L human leptin of unknown sample.
GH and PTH measurements
Previously described RIA methods were used to measure human GH levels (16) and PTH levels (17) .
Other measurements
Serum creatinine and albumin were measured by standard laboratory methods (Hitachi 747, Boehringer Mannheim Corp., Indianapolis, IN). ␤ 2 -Microglobulin was measured using an immunoenzymometric method (Tosoh 1200 DX, Foster City, CA).
Data analysis
Data analysis was performed using a statistical software program (Jandel scientific software 2.0, San Rafael, CA). Quantitative results are reported as the mean Ϯ sd. Paired t test and Mann-Whitney rank sum test, with level of significance set at P Ͻ 0.05, were performed to assess significant differences in parameters of patients and controls.
Results
Predialysis plasma leptin concentrations in ESRD patients ranged from 1.7-245 g/L, with mean values of 26.8 Ϯ 5.7 g/L for men and 38.3 Ϯ 5.6 g/L for women (Fig. 1) . Mean values in patients with ESRD of both sexes were significantly higher (P Ͻ 0.001) than those obtained in normal volunteers (11.9 Ϯ 3.1 g/L for men and 21.2 Ϯ 3.0 g/L for women). Linear regression analyses showed that in both ESRD and control groups, leptin levels correlated directly with BMI (r ϭ 0.77 and 0.78 for ESRD men and women, respectively, and r ϭ 0.78 and 0.71 for control men and women); all correlations were statistically significant (P Ͻ 0.001). The rate of increase in leptin concentrations with increasing BMI was significantly greater in ESRD patients (5.5 g/L/U BMI for men and 6.6 g/L/U BMI for women) than in normal subjects (1.4 g/L/U BMI for men and 2.6 g/L/U BMI for women). Analysis with the Mann-Whitney rank sum test showed that the differences in the medians of the ESRD and control subjects were greater than would be expected by chance (P Ͻ 0.001). Separation of our patient population into nonobese and obese (BMI Ͼ26.7 for men and Ͼ27.8 for women) groups revealed that the difference in the medians between ESRD and normal subjects remained significant in both nonobese individuals (P ϭ 0.045 for men and P ϭ 0.046 for women) and obese individuals (P Ͻ 0.001 for both men and women).
Postdialysis leptin concentrations were similar to predialysis leptin values (Fig. 2) . No correlation of leptin concentrations with age or race was observed in ESRD patients (data not shown) in agreement with previous results obtained in normal subjects (10, 18) .
Western blot analysis of samples from ESRD patients who had high leptin concentrations compared to BMI-matched control subjects showed that the ESRD specimens contained high levels of leptin protein that had the same molecular form as the native protein, and that immunoreactive degradation products were not present (Fig. 3) . Estimation of the leptin concentration by Western blot, based on densitometry scanning (10), yielded a mean concentration of 84% of the concentrations determined by RIA. The markedly elevated leptin concentrations that were observed in many ESRD patients did not correlate with weight changes in patients over a period of 4 months (Fig. 4) .
Leptin levels did not correlate with residual renal function, determined by measuring creatinine clearance, or adequacy of dialysis, estimated by urea reduction ratio (data not shown). Correlations of GH (r ϭ 0.20), ␤ 2 -microglobulin (r ϭ 0.29) and PTH (r ϭ 0.23) with leptin concentrations were not significant (P Ͼ 0.05). Similarly, there was a poor correlation of leptin levels with serum creatinine (r ϭ 0.13) and with the number of years on hemodialysis (r ϭ 0.20). Figure 5 presents leptin levels as a function of primary renal disease. There was a tendency toward higher leptin levels in patients with diabetes or primary hypertension compared to patients with other etiologies, but the association was not statistically significant.
Discussion
We investigated the possible involvement of the kidney in leptin elimination by evaluating plasma leptin levels in patients with ESRD. If glomerular filtration is a major route of leptin clearance, then impaired renal function should result in the accumulation of leptin in a manner analogous to the well documented effects of ESRD on plasma levels of PRL (19) , PTH degradation fragments, and GHs (20, 21) . Our results clearly show that leptin concentrations are increased in ESRD patients. Median levels were significantly greater in chronic renal failure patients than in normal subjects. Comparison of leptin concentrations of ESRD and control subjects in relation to BMI showed that leptin concentrations were higher in ESRD subjects regardless of their degree of adiposity.
Western blot analysis of ESRD plasma revealed a single band at 16 kDa with no evidence of smaller products, suggesting that most of the leptin was not due to degraded molecules but to full-length protein. Although the Western blot technique cannot distinguish between the folded (active) and unfolded (inactive) leptin forms, it is reasonable to suggest that the accumulated leptin in ESRD patients is in the native form; leptin is very stable on storage in plasma or serum (10) and is stable for 48 h at 20 C even in whole blood (M. Landt, unpublished observation).
A proposed biological effect of leptin is to regulate body mass by depressing appetite and by increasing metabolic rate (4 -6) . Therefore, accumulation of circulating leptin in patients with ESRD could influence body weight. We found no correlation between the leptin concentration and weight changes in the previous 4 months, suggesting that the increased leptin is not exerting a physiological effect. This result is consistent with previous findings that most obese individuals are insensitive to endogenous leptin production (8, 10) .
There was no association between leptin levels and several parameters commonly used to assess the extent of renal function impairment. Leptin concentrations did not correlate with creatinine clearance, serum creatinine, ␤ 2 -microglobulin, PTH, or GH concentrations. There was no association of leptin accumulation with length on hemodialysis of patients. Additionally, two surgically anephric individuals in our study had low leptin levels. These results raise the possibility that the increased leptin concentrations seen in ESRD patients might not be due entirely to simple impairment of renal elimination; changes in production or secondary effects of uremia on nonrenal elimination of leptin may also be important causes. Also, all of these parameters (creatinine, ␤ 2 -microglobulin, PTH, and GH) are highly imperfect in measuring the extent of renal impairment. Depending on the dialyzer used, all of these substances may be subject to some exchange and removal by dialysis. Additionally, GH and PTH are subject to physiological variation (e.g. nonrenal elimination and secondary hyperparathyroidism) that complicates the correlation of elevated levels with renal impairment. Further studies will be aimed at differentiating increased production from decreased elimination in ESRD patients, and it will also be important to directly measure leptin clearance across the renal bed; those studies are now in progress.
